CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukemia

International Journal of Oncology

Volumn 33, Issue 1, 2008, Pages 169-174

  Mainou Fowler, Tryfonia ^a   Porteous, Alistair ^a   Nicolle, Annette ^a   Proctor, Stephen John ^a   Anderson, John James ^a   Summerfiled, Geoffrey ^b  

^a School of Clinical and Laboratory Sciences   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Antigen quantification; B cell chronic lymphocytic leukaemia; CD31; CD38; Prognosis

Indexed keywords

CD31 ANTIGEN; CD38 ANTIGEN;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK FACTOR; B CELL LEUKEMIA; IMMUNOLOGY; MIDDLE AGED; MORTALITY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD31; ANTIGENS, CD38; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RISK FACTORS;

EID: 51049099197     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Zwiebel JA and Cheson BD: Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 25: 42-59, 1998.
2. H gene mutation status in pathogenesis and clinical course. Leukemia 16: 993-1007, 2002.
3. Del Principe MI, Del Poeta G, Buccisano F, et al: Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 108: 853-861, 2006.
4. Orchard JA, Ibbotson RE, Davis Z, et al: ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 363: 105-111, 2004.
5. Mainou-Fowler T, Dignum HM, Proctor SJ and Summerfield GP: The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma 45: 455-462, 2004.
6. Funaro A, Spagnoli GC, Ausiello CM, et al: Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J Immunol 145: 2390-2396, 1990.
7. Zapo S, Rugari E, Dono M, Taborelli G, Malavasi F and Ferrarini M: CD38 signaling by agonistic monoclonal antibodies prevents apoptosis of human germinal center B cells. Eur J Immunol 24: 1218-1222, 1994.
8. Kumagai M, Coustan-Smith E, Murray DJ, et al: Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med 181: 1101-1110, 1995.
9. Deaglio S, Morra M, Mallone R, et al: Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 160: 395-402, 1998.
10. Jackson DE, Gully LM, Henshall TL, Mardell CE and Macardle PJ: Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) is associated with a naïve B-cell phenotype in human tonsils. Tissue Antigens 56: 105-116, 2000.
11. + precursors. Leuk Lymphoma 45: 2205-2213, 2004.
12. Gao C, Sun W, Christophidou-Solomidou M, et al: PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis. Blood 102: 169-179, 2003.
13. Ilan N, Mohsenin A, Cheung L and Madri JA: PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signalling characteristics. FASEB J 15: 362-372, 2001.
14. Deaglio S, Metha K and Malavasi F: Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 25: 1-12, 2001.
15. Newman PJ: Switched at birth: a new family for PECAM-1. J Clin Invest 103: 5-9, 1999.
16. Vallario A, Chilosi M, Adami F, et al: Human myeloma cells express the CD38 ligand CD31. Br J Haematol 105: 441-444, 1999.
17. Ibrahim S, Jilani I, O'Brien S, et al: Clinical relevance of the expression of CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukaemia. Cancer 97: 1914-1919, 2003.
18. Morabito F, Mangiola M, Stelitano C, Diaglio S, Callea V and Malavasi F: Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukaemia B-cells: anecdotal observations or pathogenetic hypothesis for the clinical outcome? Haematologica 88: 354-355, 2003.
19. Jaksic O, Paro MMK, Skelin IK, Kusec R, Pejsa V and Jaksic B: CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood 103: 1968-1969, 2004.
20. Mainou-Fowler T, Dignum H, Taylor PRA and Dickinson AM: Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol 118: 755-761, 2002.
21. Silvennoinen O, Nishigaki H, Kitanaka A, et al: CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C-gamma and phosphatidylinositol 3-kinase. J Immunol 156: 100-107, 1996.
22. Tenca C, Merlo A, Zarcone D, et al: Death of T cell precursors in the human thymus; a role for CD38. Int Immunol 15: 1105-1116, 2003.
23. Jackson DE: The unfolding tale of PECAM-1. FEBS Lett 540: 7-14, 2003.
24. Deaglio S, Capobianco A, Bergui L, et al: CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 102: 2146-2155, 2003.
25. Deaglio S, Vaisitti T, Aydin S, Ferrero E and Malavasi F: In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 108: 1135-1144, 2006.